Skip to main content

Advertisement

SpringerLink
Log in

Loss of Fhit expression is associated with poorer survival in gastric cancer but is not an independent prognostic marker

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Several studies have reported conflicting results regarding correlations of the loss of Fhit expression with clinicopathological parameters in gastric cancer. We investigated the immunohistochemical expression of Fhit in 362 cases of sporadic advanced gastric adenocarcinoma. The series included 64 cases with microsatellite instability associated with defective mismatch repair genes. Fhit expression resulted absent in 72% of the tumors analyzed. Absence of Fhit expression was more frequent in cases with diffuse and mixed histotype compared to the intestinal histotype (P=0.009). Absence of Fhit expression also correlated with tumor stage (P<0.001), lymph node involvement (P<0.001), presence of distant metastasis (P=0.033), and increasing histological grade (P=0.005). Retained Fhit expression also correlated with microsatellite instability as 61% of instable tumors had lost Fhit expression compared to 74% of microsatellite stable cancers (P=0.050). While loss of Fhit correlates with poorer survival in univariate analysis, it is not an independent prognostic factor in multivariate analysis and is thus not of clinical utility.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Baffa R, Veronese ML, Santoro R et al (1998) Loss of FHIT expression in gastric carcinoma. Cancer Res 58:4708–4714

    PubMed  CAS  Google Scholar 

  2. Barnes LD, Garrison PN, Siprashvili Z et al (1996) Fhit, a putative tumor suppressor in humans, is a dinucleoside 5’,5”‘-P1,P3-triphosphate hydrolase. Biochemistry 35:11529–11535

    Article  PubMed  CAS  Google Scholar 

  3. Capuzzi D, Santoro E, Hauck WW et al (2000) Fhit expression in gastric adenocarcinoma: correlation with disease stage and survival. Cancer 88:24–34

    Article  PubMed  CAS  Google Scholar 

  4. Chen YJ, Chen PH, Lee MD et al (1997) Aberrant FHIT transcripts in cancerous and corresponding non-cancerous lesions of the digestive tract. Int J Cancer 72:955–958

    Article  PubMed  CAS  Google Scholar 

  5. Croce CM, Sozzi G, Huebner K (1999) Role of FHIT in human cancer. J Clin Oncol 17:1618–1624

    PubMed  CAS  Google Scholar 

  6. Gemma A, Hagiwara K, Ke Y et al (1997) FHIT mutations in human primary gastric cancer. Cancer Res 57:1435–1437

    PubMed  CAS  Google Scholar 

  7. Hermanek P, Sobin L (1992) TNM classification of malignant tumours, UICC, 2nd revision. Springer, Berlin Heidelberg New York

    Google Scholar 

  8. Huiping C, Kristjansdottir S, Bergthorsson JT et al (2002) High frequency of LOH, MSI and abnormal expression of FHIT in gastric cancer. Eur J Cancer 38:728–735

    Article  PubMed  CAS  Google Scholar 

  9. Ishii H, Dumon KR, Vecchione A et al (2001) Effect of adenoviral transduction of the fragile histidine triad gene into esophageal cancer cells. Cancer Res 61:1578–1584

    PubMed  CAS  Google Scholar 

  10. Ishii H, Zanesi N, Vecchione A et al (2003) Regression of upper gastric cancer in mice by FHIT gene delivery. Faseb J 17:1768–1770

    PubMed  CAS  Google Scholar 

  11. Kawaguchi K, Yashima K, Koda M et al (2004) Fhit expression in human gastric adenomas and intramucosal carcinomas: correlation with Mlh1 expression and gastric phenotype. Br J Cancer 90:672–677

    Article  PubMed  CAS  Google Scholar 

  12. Kitamura A, Yashima K, Okamoto E et al (2001) Reduced Fhit expression occurs in the early stage of esophageal tumorigenesis: no correlation with p53 expression and apoptosis. Oncology 61:205–211

    Article  PubMed  CAS  Google Scholar 

  13. Lauren P (1965) The two histological main types of gastric carrcinoma: diffuse and so called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 64:31–49

    PubMed  CAS  Google Scholar 

  14. Lee HS, Lee HK, Kim HS et al (2003) Tumour suppressor gene expression correlates with gastric cancer prognosis. J Pathol 200:39–46

    Article  PubMed  CAS  Google Scholar 

  15. Lee SH, Kim CJ, Park HK et al (2001) Characterization of aberrant FHIT transcripts in gastric adenocarcinomas. Exp Mol Med 33:124–130

    PubMed  CAS  Google Scholar 

  16. Lee SH, Kim HY, Kim TJ et al (2002) Aberrant splicing of FHIT transcripts in human gastric cancer cell lines. Res Commun Mol Pathol Pharmacol 112:39–49

    PubMed  CAS  Google Scholar 

  17. Lee SH, Kim WH, Kim HK et al (2001) Altered expression of the fragile histidine triad gene in primary gastric adenocarcinomas. Biochem Biophys Res Commun 284:850–855

    Article  PubMed  CAS  Google Scholar 

  18. Negrini M, Monaco C, Vorechovsky I et al (1996) The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res 56:3173–3179

    PubMed  CAS  Google Scholar 

  19. Noguchi T, Muller W, Wirtz HC et al (1999) FHIT gene in gastric cancer: association with tumour progression and prognosis. J Pathol 188:378–381

    Article  PubMed  CAS  Google Scholar 

  20. Ohta M, Inoue H, Cotticelli MG et al (1996) The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84:587–597

    Article  PubMed  CAS  Google Scholar 

  21. Rocco A, Schandl L, Chen J et al (2003) Loss of FHIT protein expression correlates with disease progression and poor differentiation in gastric cancer. J Cancer Res Clin Oncol 129:84–88

    PubMed  CAS  Google Scholar 

  22. Sarli L, Bottarelli L, Azzoni C et al (2004) Abnormal Fhit protein expression and high frequency of microsatellite instability in sporadic colorectal cancer. Eur J Cancer 40:1581–1588

    Article  PubMed  CAS  Google Scholar 

  23. Skopelitou AS, Mitselou A, Katsanos KH et al (2003) Immunohistochemical expression of Fhit protein in Helicobacter pylori related chronic gastritis, gastric precancerous lesions and gastric carcinoma: correlation with conventional clinicopathologic parameters. Eur J Gastroenterol Hepatol 15:515–523

    Article  PubMed  CAS  Google Scholar 

  24. Sorio C, Baron A, Orlandini S et al (1999) The FHIT gene is expressed in pancreatic ductular cells and is altered in pancreatic cancers. Cancer Res 59:1308–1314

    PubMed  CAS  Google Scholar 

  25. Sozzi G, Veronese ML, Negrini M et al (1996) The FHIT gene 3p14.2 is abnormal in lung cancer. Cell 85:17–26

    Article  PubMed  CAS  Google Scholar 

  26. Stec-Michalska K, Antoszczyk S, Klupinska G et al (2005) Loss of FHIT expression in gastric mucosa of patients with family histories of gastric cancer and Helicobacter pylori infection. World J Gastroenterol 11:17–21

    PubMed  CAS  Google Scholar 

  27. Tamura G, Sakata K, Nishizuka S et al (1997) Analysis of the fragile histidine triad gene in primary gastric carcinomas and gastric carcinoma cell lines. Genes Chromosomes Cancer 20:98–102

    Article  PubMed  CAS  Google Scholar 

  28. Vecchione A, Sevignani C, Giarnieri E et al (2004) Inactivation of the FHIT gene favors bladder cancer development. Clin Cancer Res 10:7607–7612

    Article  PubMed  CAS  Google Scholar 

  29. Zanesi N, Fidanza V, Fong LY et al (2001) The tumor spectrum in FHIT-deficient mice. Proc Natl Acad Sci USA 98:10250–10255

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Emma Bragantini and Stefano Barbi contributed equally. This work was supported by: Fondazione Cassa di Risparmio di Verona (Bando 2004) to P.S. Moore; Associazione Italiana Ricerca sul Cancro (AIRC), Milan, Italy to G. de Manzoni; CNR and MIUR, Rome, Italy to Aldo Scarpa and Franco Rovielle.

Author information

Authors and Affiliations

  1. Dipartimento di Patologia, Sezione Anatomia Patologica, Università di Verona, Strada Le Grazie, 8, 37134, Verona, Italy

    Emma Bragantini, Stefano Barbi, Stefania Beghelli, Patrick S. Moore & Aldo Scarpa

  2. Prima Chirurgia Clinicizzata, Università di Verona, Ospedale Borgo Trento, Verona, Italy

    Giovanni de Manzoni

  3. Divisione di Chirurgia Oncologica, Università di Siena, Policlinico Le Scotte, Siena, Italy

    Franco Roviello

  4. Servizio di Anatomia Patologica, Ospedale Borgo Trento, Verona, Italy

    Anna Tomezzoli

  5. Dipartimento Patologia Umana e Oncologia, Sezione Anatomia Patologica, Università di Siena, Siena, Italy

    Carla Vindigni

  6. Department of Urology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, , PA, USA

    Raffaele Baffa

Authors
  1. Emma Bragantini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefano Barbi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stefania Beghelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Patrick S. Moore
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Giovanni de Manzoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Franco Roviello
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Anna Tomezzoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Carla Vindigni
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Raffaele Baffa
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Aldo Scarpa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrick S. Moore.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bragantini, E., Barbi, S., Beghelli, S. et al. Loss of Fhit expression is associated with poorer survival in gastric cancer but is not an independent prognostic marker. J Cancer Res Clin Oncol 132, 45–50 (2006). https://doi.org/10.1007/s00432-005-0045-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-005-0045-9

Key words

Search

Navigation